LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-051, which is in Phase 1/2a clinical trial for blood cancers, including chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia; and LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is also developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 and LAVA-1278, which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use. The company was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.

LAVA Therapeutics N.V.

A biotechnology company focused on developing gamma delta T cell engagers to potently and precisely fight cancer.

NASDAQ:LVTX

Lava Therapeutics

Last Close

1.85

12/11 20:06

Market Cap

50.22M

Beta: −0.50

Volume Today

21.50K

Avg: 70.82K

PE Ratio

−0.89

PFCF: 7.59

locale

market

industry

website

ipo date

Earnings

Earnings per Share (Estimate*)

Revenue (Estimate*)

Metrics